

Supplemental online content for:

## **A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events**

Jarushka Naidoo, MBBCh; Jiajia Zhang, MD, PhD; Evan J. Lipson, MD; Patrick M. Forde, MBBCh; Karthik Suresh, MD; Kendall F. Moseley, MD; Seema Mehta, MD; Shawn G. Kwatra, MD; Alyssa M. Parian, MD; Amy K. Kim, MD; John C. Probasco, MD, PhD; Rosanne Rouf, MD; Jennifer E. Thorne, MD, PhD; Satish Shanbhag, MD; Joanne Riemer, RN, BSN; Ami A. Shah, MD; Drew M. Pardoll, MD, PhD; Clifton O. Bingham III, MD; Julie R. Brahmer, MD, MHS; and Laura C. Cappelli, MD, MHS

*J Natl Compr Canc Netw* 2019;17(6):712–720

**eFigure 1:** Representative Templates to and From IR-Tox Team


**eFigure 2:** CONSORT Diagram

**eFigure 3:** Selected Results of the Electronic Postpilot Survey

**eAppendix 1:** Postpilot Questionnaire About the IR-Tox Team

**eAppendix 2:** Clinical Outcomes of Controlled irAEs





**eFigure 3.** Selected results of the electronic postpilot survey sent to oncology providers in the cancer center, after the IR-tox team pilot program. Abbreviations: IR-tox, immune-related toxicity; irAE, immune-related adverse event.

## Appendix 1. Postpilot Questionnaire About the IR-Tox Team

Q1	What area of oncology do you primarily work in?
Q2	What type of provider are you?
Q3	How often do you prescribe immunotherapy for cancer treatment/evaluate patients on immunotherapy?
Q4	What kind of immunotherapy do you prescribe? (check all that apply)
Q5	How often do you encounter suspected immune-related toxicity?
Q6	How often do you encounter immune-related toxicity that requires an intervention?
Q7	Have you contacted the IR-tox team?
Q8	What topic(s) did you ask the team about? (check all that apply)
Q9	Did you use the specific suggestions provided by the IR-tox team?
Q10	Did the IR-tox team recommendations change your approach to evaluation or management of immune-related toxicity?
Q11	Did you find the IR-tox team service to be helpful?
Q12	What format would you prefer to contact the IR-tox team? (choose one)
Q13	What other resources could the IR-tox team provide that would be helpful? (check all that apply)
Q14	How would you prefer to access information on IR-tox?
Q15	Do you think there would be a benefit to a regular tumor board–style meeting about IR-tox?
Q16	How often should a tumor board–style meeting for IR-tox take place?
Q17	Would you support an immune-related toxicity registry/enrollment of patients with irAEs for research purposes?
Q18	Do you want a separate irAEs outpatient clinic?
Q19	Do you want a separate irAEs urgent care?
Q20	Would you attend an irAEs masterclass if offered?
Q21	Please provide any additional feedback

Abbreviations: IR-tox, immune-related toxicity; irAE, immune-related adverse event.

## Appendix 2. Clinical Outcomes of Confirmed irAEs

Clinical Outcomes	Grade 1–2 (n=47; 60%) n (%)	Grade ≥3 (n=32; 40%) n (%)
irAE1 <sup>a</sup>		
Completely resolved	2 (4)	3 (9)
Improved	32 (68)	20 (63)
Stabilized	6 (13)	3 (9)
Worsened	0 (0)	3 (9)
irAE2 <sup>b</sup>		
Completely resolved	3 (7)	0 (0)
Improved	2 (4)	1 (3)
Stabilized	2 (4)	1 (3)
Worsened	0 (0)	1 (3)

Abbreviation: irAE, immune-related adverse event.

<sup>a</sup>First irAE prompting referral.

<sup>b</sup>Second irAE prompting referral.